<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327037</url>
  </required_header>
  <id_info>
    <org_study_id>BelarusianPediatric_NK_Pilot</org_study_id>
    <nct_id>NCT04327037</nct_id>
  </id_info>
  <brief_title>Safety of Expanded Haploidentical Natural Killer Cells for Leukemia</brief_title>
  <official_title>Pilot Study of Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belarusian Research Center for Pediatric Oncology, Hematology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Belarusian Research Center for Pediatric Oncology, Hematology and Immunology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the safety of ex vivo expanded haploidentical
      natural killer (NK) cells for patients with leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunotherapy with natural killer (NK) cells may improve the results of treatment for
      patients with cancer. However, for better efficiency high doses of NK cells are required. For
      this purpose, NK cells were expanded in the presence of feeder K562 cells gene-modified for
      expression 4-1BBL and membrane bound IL-21. In the result of expansion, large number of
      activated NK cells are obtained.

      Protocol of immunotherapy includes conditioning (fludarabine + cyclophosphamide or any other
      protocol of chemotherapy) followed by expanded NK cells intravenous infusion. To sustain
      proliferation of donor NK cells in vivo patients receive 6 doses of Il-2 every second day. 10
      patients will be enrolled in phase I to test different doses of NK cells: 20, 50, 70, 100 and
      &gt;100 x 10^6/kg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>1 months</time_frame>
    <description>Adverse events will be graded according to the CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of persistence of adoptively-transferred haploidentical NK cells</measure>
    <time_frame>1 months</time_frame>
    <description>Analysis of donor chimerism at +2, 6, 10, 14, 21, 28 days after NK infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of disease response</measure>
    <time_frame>1 months post infusion</time_frame>
    <description>Analysis of blast cells content in bone marrow by cytomorphology or detection of MRD level by flow/PCR before and after immunotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to leukocytes and platelets recovery</measure>
    <time_frame>2 months post infusion</time_frame>
    <description>Days of platelets (&gt;50x10^9/L) and leukocytes (&gt;1x10^9/L) recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of T, B, NK, activated T and NK cells after immunotherapy</measure>
    <time_frame>1 months post infusion</time_frame>
    <description>Analysis of T, B, NK, activated T and NK cells numbers (cells/microL) at +2, 6, 10, 14, 21, 28 days after NK infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Leukemia, Acute Myeloid</condition>
  <condition>Leukemia, Acute Lymphoblastic</condition>
  <arm_group>
    <arm_group_label>NK cells + IL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After cycle of chemotherapy patient receive one intravenous infusion of expanded haploidentical NK cells on day 0. On alternate days, 6 doses of subcutaneous IL-2 is administered with start on day -1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Expanded Haploidentical Natural Killer cells</intervention_name>
    <description>One dose (from 20x to &gt;100x 10^6 /kg) of expanded haploidentical NK cells</description>
    <arm_group_label>NK cells + IL-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>6 doses of IL-2 (1 Ã— 10^6 units/m2) from -1 day every other day.</description>
    <arm_group_label>NK cells + IL-2</arm_group_label>
    <other_name>Ronkoleukinum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients:

          -  Relapsed acute myeloid or lymphoblastic leukemia

          -  Primary refractory myeloid or lymphoblastic leukemia

          -  Karnofsky or Lansky performance scale greater or equal to 70

          -  Written informed consent

        Donor:

          -  Haploidentical family donor

          -  &gt; 18 years old

          -  Donor suitable for cell donation and apheresis according to standard criteria

          -  Written informed consent

        Exclusion Criteria:

        Patients:

          -  Uncontrolled infection

          -  Severe hepatic dysfunction: SGOT or SCPT &gt;=5x upper limit of normal for age

          -  Positive serology for human immunodeficiency virus (HIV)

        Donors:

          -  Pregnancy or breast feeding

          -  Positive serology for HIV, hepatitis B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Aleinikova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Belarussian Research Center for Pediatric Oncology, Hematology and Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatsiana Shman</last_name>
    <phone>+375296341853</phone>
    <email>shman@oncology.by</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Aleinikova</last_name>
    <phone>80172871065</phone>
    <email>aleinikova2004@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Belarussian Research Center for Pediatric Oncology, Hematology and Immunology</name>
      <address>
        <city>Minsk</city>
        <state>Minsk Region</state>
        <zip>223053</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatsiana Shman</last_name>
      <phone>+37529 6341853</phone>
      <email>shman@oncology.by</email>
    </contact>
    <investigator>
      <last_name>Olga Aleinikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Natural killer cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

